Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.

OBJECTIVE: There is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics...

ver descrição completa

Detalhes bibliográficos
Autores: Corma-Gómez A, Macías J, Téllez F, Morano L, Rivero A, Serrano M, Ríos MJ, Vera-Méndez FJ, Santos M, Real LM, Palacios R, Santos IL, Geijo P, Imaz A, Merino D, Galindo MJ, Reus-Bañuls S, López-Ruz MÁ, Galera C, Pineda JA, RIS-HEP13 and GEHEP 011 study groups
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p8245
Acesso em linha:https://isabial.portalinvestigacion.com/publicaciones8245
https://journals.lww.com/aidsonline/Abstract/2021/11010/Kinetics_of_emergence_of_liver_complications_in.6.aspx
Access Level:acceso abierto
Palavra-chave:direct-acting antivirals
hepatitis C virus
hepatocellular carcinoma
HIV/hepatitis C virus-coinfection
liver decompensation
sustained virological response
id ES_c4e67695e6039b16b16e8bf3ca1c4156
oai_identifier_str oai:isabial.fundanetsuite.com:p8245
network_acronym_str ES
network_name_str España
repository_id_str
spelling Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.Corma-Gómez AMacías JTéllez FMorano LRivero ASerrano MRíos MJVera-Méndez FJSantos MReal LMPalacios RSantos ILGeijo PImaz AMerino DGalindo MJReus-Bañuls SLópez-Ruz MÁGalera CPineda JARIS-HEP13 and GEHEP 011 study groupsdirect-acting antiviralshepatitis C virushepatocellular carcinomaHIV/hepatitis C virus-coinfectionliver decompensationsustained virological responseOBJECTIVE: There is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of liver-related events appearance in this setting. DESIGN: A multicentric prospective cohort study. METHODS: HCV-monoinfected and HIV/HCV-coinfected patients from GEHEP-011 cohort, whose inclusion criteria were had achieved SVR with DAA-based therapy; liver stiffness prior to starting treatment at least 9.5 kPa; and available liver stiffness measurement at SVR. SVR was considered as the baseline time-point. RESULTS: One thousand and thirty-five patients were included, 664 (64%) coinfected with HIV. Before DAA-based therapy, 63 (6.1%) individuals showed decompensated cirrhosis. After SVR, 51 (4.9%) patients developed liver complications. Median (Q1-Q3) time to the emergence of hepatic events was hepatic encephalopathy 11 (7-24) months, ascites 14 (6-29) months, hepatocellular carcinoma (HCC) 17 (11-42) months and portal hypertension gastrointestinal bleeding (PHGB) 28 (22-38) months (P = 0.152). We define two profiles of liver complications: those emerging earlier (encephalopathy and ascites) and, those occurring continuously during the follow-up (HCC, PHGB) [median (Q1-Q3) time to emergence 12.7 (6.6-28.2) months vs. 25.4 (12.5-41.53) months, respectively (P = 0.026)]. CONCLUSION: The vast majority of HCV-infected patients who develop liver complications after reaching SVR with DAA do it within 3 years after SVR time-point. Specifically, hepatic encephalopathy and ascites do not usually emerge after this period. Conversely, HCC and PHGB may occur in longer term. It is critical to identify patients at risk of developing hepatic events to continue performing surveillance for them.LIPPINCOTT WILLIAMS & WILKINS2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones8245https://journals.lww.com/aidsonline/Abstract/2021/11010/Kinetics_of_emergence_of_liver_complications_in.6.aspxAIDSISSN: 02699370ISSNe: 14735571reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p82452026-06-12T10:20:37Z
dc.title.none.fl_str_mv Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
title Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
spellingShingle Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
Corma-Gómez A
direct-acting antivirals
hepatitis C virus
hepatocellular carcinoma
HIV/hepatitis C virus-coinfection
liver decompensation
sustained virological response
title_short Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
title_full Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
title_fullStr Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
title_full_unstemmed Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
title_sort Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
dc.creator.none.fl_str_mv Corma-Gómez A
Macías J
Téllez F
Morano L
Rivero A
Serrano M
Ríos MJ
Vera-Méndez FJ
Santos M
Real LM
Palacios R
Santos IL
Geijo P
Imaz A
Merino D
Galindo MJ
Reus-Bañuls S
López-Ruz MÁ
Galera C
Pineda JA
RIS-HEP13 and GEHEP 011 study groups
author Corma-Gómez A
author_facet Corma-Gómez A
Macías J
Téllez F
Morano L
Rivero A
Serrano M
Ríos MJ
Vera-Méndez FJ
Santos M
Real LM
Palacios R
Santos IL
Geijo P
Imaz A
Merino D
Galindo MJ
Reus-Bañuls S
López-Ruz MÁ
Galera C
Pineda JA
RIS-HEP13 and GEHEP 011 study groups
author_role author
author2 Macías J
Téllez F
Morano L
Rivero A
Serrano M
Ríos MJ
Vera-Méndez FJ
Santos M
Real LM
Palacios R
Santos IL
Geijo P
Imaz A
Merino D
Galindo MJ
Reus-Bañuls S
López-Ruz MÁ
Galera C
Pineda JA
RIS-HEP13 and GEHEP 011 study groups
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv direct-acting antivirals
hepatitis C virus
hepatocellular carcinoma
HIV/hepatitis C virus-coinfection
liver decompensation
sustained virological response
topic direct-acting antivirals
hepatitis C virus
hepatocellular carcinoma
HIV/hepatitis C virus-coinfection
liver decompensation
sustained virological response
description OBJECTIVE: There is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of liver-related events appearance in this setting. DESIGN: A multicentric prospective cohort study. METHODS: HCV-monoinfected and HIV/HCV-coinfected patients from GEHEP-011 cohort, whose inclusion criteria were had achieved SVR with DAA-based therapy; liver stiffness prior to starting treatment at least 9.5 kPa; and available liver stiffness measurement at SVR. SVR was considered as the baseline time-point. RESULTS: One thousand and thirty-five patients were included, 664 (64%) coinfected with HIV. Before DAA-based therapy, 63 (6.1%) individuals showed decompensated cirrhosis. After SVR, 51 (4.9%) patients developed liver complications. Median (Q1-Q3) time to the emergence of hepatic events was hepatic encephalopathy 11 (7-24) months, ascites 14 (6-29) months, hepatocellular carcinoma (HCC) 17 (11-42) months and portal hypertension gastrointestinal bleeding (PHGB) 28 (22-38) months (P = 0.152). We define two profiles of liver complications: those emerging earlier (encephalopathy and ascites) and, those occurring continuously during the follow-up (HCC, PHGB) [median (Q1-Q3) time to emergence 12.7 (6.6-28.2) months vs. 25.4 (12.5-41.53) months, respectively (P = 0.026)]. CONCLUSION: The vast majority of HCV-infected patients who develop liver complications after reaching SVR with DAA do it within 3 years after SVR time-point. Specifically, hepatic encephalopathy and ascites do not usually emerge after this period. Conversely, HCC and PHGB may occur in longer term. It is critical to identify patients at risk of developing hepatic events to continue performing surveillance for them.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones8245
https://journals.lww.com/aidsonline/Abstract/2021/11010/Kinetics_of_emergence_of_liver_complications_in.6.aspx
url https://isabial.portalinvestigacion.com/publicaciones8245
https://journals.lww.com/aidsonline/Abstract/2021/11010/Kinetics_of_emergence_of_liver_complications_in.6.aspx
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
dc.source.none.fl_str_mv AIDS
ISSN: 02699370
ISSNe: 14735571
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418942297014272
score 15,812429

Registos relacionados